Core Insights - LifeMD, Inc. has appointed Atul Kavthekar as Chief Financial Officer to support its growth phase, with Marc Benathen departing to pursue new opportunities [1][2][6] Leadership Changes - Atul Kavthekar brings nearly three decades of experience in healthcare and technology, focusing on financial infrastructure and operational performance [2][3] - Chris Pisano has been appointed as Chief Marketing Officer, bringing over 25 years of marketing experience to enhance brand strategy and market positioning [4][6] - Jessica Friedeman will assume the role of Chief Business Officer, focusing on enterprise and employer health offerings while continuing her leadership in women's health [5][6] Strategic Focus - Kavthekar will work with the technology team to position LifeMD as an AI-first healthcare company, aiming to improve patient access and clinical outcomes [3][4] - The leadership changes are designed to leverage the strengths of the management team as LifeMD enters a new growth phase [6] Employment Inducement Grant - As part of his employment, Kavthekar will receive 675,000 restricted stock units, with vesting conditions based on service and performance targets [7] Company Overview - LifeMD is a leading provider of virtual primary care services, offering telemedicine and specialized treatment across over 200 conditions [8]

Core Viewpoint - LifeMD Inc is strategically focusing on its core telehealth and pharmacy services by divesting its WorkSimpli business, which is expected to enhance operational efficiency and market share growth [1][5]. Financial Performance - The stock price target set by Loop Capital Markets is $10, indicating a potential upside of approximately 42.27% from its current trading price of $3.87, which reflects a slight decrease of 4.68% [2][5]. - LifeMD is trading at a low multiple of 0.796 times its trailing twelve-month sales, suggesting potential upside if multiples revert to higher levels [3]. Market Activity - The stock has fluctuated between a low of $3.86 and a high of $4.30 today, with a market capitalization of approximately $186.3 million and a trading volume of 1,062,494 shares on the NASDAQ exchange [4]. - Over the past year, the stock reached a high of $15.84 and a low of $2.56, indicating significant volatility [4]. Growth Drivers - The recent launch of the Wegovy pill is anticipated to drive growth within LifeMD's GLP-1 vertical, further strengthening its market position [3][5].

Core Viewpoint - LifeMD, Inc. (LFMD) has experienced a sustained dip over the past year, creating a bullish entry point for potential investors as the company is currently trading at its lowest multiple to trailing twelve months earnings [1] Group 1: Company Overview - LifeMD, Inc. is positioned as an attractive investment opportunity due to its low trading multiples, which may indicate undervaluation [1] Group 2: Market Context - The equity market is characterized by daily price fluctuations that can lead to significant wealth creation or destruction over the long term [1] - Pacifica Yield focuses on long-term wealth creation by targeting undervalued high-growth companies, high-dividend stocks, REITs, and green energy firms [1]

Financial Performance - Telehealth revenue for the year ended December 31, 2025, was approximately $194.1 million, a 25% increase from $154.8 million in 2024, driven by a rise in telehealth subscription revenue [207]. - Cost of telehealth revenue increased by approximately 29% to $27.7 million in 2025, compared to $21.4 million in 2024, maintaining a consistent cost ratio of 14% of telehealth revenues [208]. - Gross profit rose by approximately 25% to $166.3 million in 2025, with gross profit margin remaining stable at 86% [209]. - Total operating expenses for 2025 were approximately $174.0 million, a 13% increase from $153.8 million in 2024, primarily due to a $16.0 million rise in selling and marketing expenses [210]. - The company recorded a net loss from continuing operations of approximately $10.2 million in 2025, an improvement from a loss of $23.2 million in 2024 [207]. - Net income from discontinued operations was $25.9 million in 2025, compared to $2.3 million in 2024, contributing to a net income of $15.6 million for the year [207]. Cash Flow and Working Capital - Working capital increased by approximately $25.3 million during 2025, with current liabilities decreasing by approximately $25.8 million [214]. - Net cash provided by operating activities for the year ended December 31, 2025, was approximately $8.3 million, a decrease from $17.5 million in 2024 [215]. - Net cash provided by investing activities for the year ended December 31, 2025, was approximately $6.9 million, compared to net cash used of $11.5 million in 2024, primarily due to net proceeds from the WorkSimpli sale of $19.4 million [217]. - Net cash used in financing activities for the year ended December 31, 2025, was approximately $13.4 million, an increase from $4.1 million in 2024, driven by total debt repayments of $18.7 million [218]. - The Company expects existing cash of $36.8 million as of December 31, 2025, to be sufficient to fund planned operating expenses and capital expenditures for at least the next 12 months [222]. Strategic Initiatives - The company launched acceptance of private health insurance for virtual primary care services in June 2024, expanding to Medicare beneficiaries in April 2025 [203]. - The acquisition of Optimal Human Health MD in April 2025 marked the company's entry into the women's health market, focusing on hormone health and wellness [205]. - The Company sold 762,990 shares of common stock under the ATM Sales Agreement during the year ended December 31, 2025, generating net proceeds of $8.7 million [221]. Debt and Financing - The Avenue Credit Agreement provided a convertible senior secured credit facility of up to $40 million, with $15 million funded at closing and an additional $5 million received in September 2023 [220]. - The Company recorded a loss on debt extinguishment of $1.2 million for the year ended December 31, 2025, related to the repayment of the Avenue Facility [220]. - As of December 31, 2025, there is no outstanding balance on the Avenue Facility, following the repayment of $14.0 million in principal [220]. Operating Expenses - Other operating expenses increased by approximately $2.4 million, or 28%, primarily due to higher software subscription costs [216]. - Development costs rose by approximately $489 thousand, or 7%, mainly due to technology platform improvements and amortization expenses [216]. Discontinued Operations - The company recorded a gain of $21.3 million from the sale of its majority ownership interest in WorkSimpli, classified as discontinued operations [204].

Core Insights - LifeMD, Inc. reported a GAAP net loss of $0.04 per share for Q4 2025, which was better than the expected loss of $0.07, while revenue reached $46.9 million, a 4% year-over-year increase but slightly below analyst estimates [2][5] Financial Performance - For the full year 2025, LifeMD's revenue grew by 25% to $194.1 million, and adjusted EBITDA surged by 309% to $15.3 million [3] - In Q4 2025, adjusted EBITDA increased by 348% to $4.8 million, indicating strong operational leverage [3] Product Launch and Growth - LifeMD launched oral Wegovy after the year-end, with over 80% of new weight management patients starting branded therapy, contributing to record patient sign-ups in Q1 2026 [4] - The company ended 2025 with $36.8 million in cash and no debt, positioning itself well for future growth investments [4] - LifeMD's benefits infrastructure is expected to cover approximately 220 million Americans by Q2 2026, with strong growth in its women's health offering [4]

Financial Data and Key Metrics Changes - LifeMD reported a revenue growth of 25% year-over-year for 2025, totaling $194.1 million, with a gross margin of 85.7%, a slight decrease of 50 basis points compared to the previous year [21][22] - The fourth quarter revenue grew 4% year-over-year to $46.9 million, with a gross margin of 87.1%, an increase of 570 basis points from the prior year [19][20] - GAAP net income for the fourth quarter was $19 million or $0.41 per share, including a one-time benefit from the sale of WorkSimpli [20] - Adjusted EBITDA for the fourth quarter was $4.8 million, up from $1.1 million in the previous year [22] Business Line Data and Key Metrics Changes - The weight management business is experiencing record patient acquisition, with new signups approaching 700 per day, and customer acquisition costs have declined sequentially [4][19] - The men's health segment, represented by the Rex MD brand, has approximately 215,000 active patients and returned to growth in the second half of 2025 [8][19] - Women's health is a significant focus, with investments in launching this offering, including the acquisition of Optimal Human Health [5][6] Market Data and Key Metrics Changes - LifeMD has over 322,000 active subscribers and receives more than 120,000 unique daily visitors to its websites, indicating strong brand demand [3] - The company expects to cover over 220 million lives through expanded partnerships with third-party benefits partners by the end of Q2 2026 [15] Company Strategy and Development Direction - LifeMD aims to leverage its pharmacy infrastructure as a growth driver, with plans to enhance margins and deepen patient engagement [10][14] - The company is focusing on artificial intelligence to improve care delivery and operational efficiency, with plans to launch an AI clinical decision support tool [11][12] - LifeMD is committed to building a comprehensive virtual women's healthcare offering, addressing significant unmet demand in the market [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, citing record demand in weight management and a diversifying specialty care platform [17] - The company anticipates returning to Adjusted EBITDA profitability in Q2 2026, driven by investments in patient acquisition [23] - Management highlighted the importance of insurance enablement in improving customer acquisition costs and retention [15][16] Other Important Information - LifeMD's balance sheet is strong, with nearly $37 million in cash and no debt, providing financial flexibility for growth investments [3][22] - The company is exploring partnerships with large pharmaceutical companies to expand its offerings and enhance its market position [5] Q&A Session Summary Question: Demand for Wegovy pill and brand products - Management noted strong demand for the Wegovy pill since its launch in January, with nearly doubled new patient acquisition in the weight loss business [27] Question: Revenue model for Wegovy pill - The Wegovy pill is typically priced at $249 per month, with healthy gross margins around $100 per order [30] Question: Investments in Q1 2026 - The company plans to increase sales and marketing expenditures significantly, expecting to drive patient acquisition while reducing customer acquisition costs [33] Question: Revenue ramp drivers for 2026 - Key drivers include subscriber count growth in the GLP-1 weight business, growth in women's health, and continued performance in men's health [36] Question: Stickiness of Wegovy pill versus injectable - Initial retention rates for the Wegovy pill are better than the injectable, but long-term retention is still to be determined [54] Question: Comparison with competitors - LifeMD differentiates itself through its own provider group and a comprehensive care platform, offering various specialty services [56][57] Question: Patient acquisition channels - The marketing strategy remains similar, with new partnerships delivering strong performance in patient acquisition [62] Question: Lifetime value of covered patients versus cash pay patients - Management believes that patients using insurance will have better retention and lifetime value compared to cash pay patients, though this needs further validation [64][67] Question: Subscriber count and demand for Wegovy - LifeMD has 322,000 overall subscribers, with strong demand for the Wegovy pill driving new patient acquisition [71] Question: In-house fulfillment percentage and margin lift - Approximately 70% of fulfillment is handled in-house, with an estimated margin improvement of 150-200 basis points [72]

Financial Data and Key Metrics Changes - LifeMD reported a revenue growth of 25% year-over-year for 2025, totaling $194.1 million, with a gross margin of 85.7%, a slight decrease of 50 basis points compared to the previous year [21][22] - The fourth quarter revenue grew 4% year-over-year to $46.9 million, with a gross margin of 87.1%, an increase of 570 basis points from the prior year [19][20] - GAAP net income for the fourth quarter was $19 million or $0.41 per share, including a one-time benefit from the sale of WorkSimpli [20] - Adjusted EBITDA for the fourth quarter was $4.8 million, up from $1.1 million in the previous year [20] Business Line Data and Key Metrics Changes - The weight management business is experiencing record patient acquisition, with new signups approaching 700 per day, and customer acquisition costs have declined sequentially [4][19] - The men's health segment, represented by the Rex MD brand, has approximately 215,000 active patients and returned to growth in the second half of 2025 [8] - Women's health is a significant focus, with investments in launching this offering, including acquiring Optimal Human Health MD and partnerships with recognized experts in the field [5][6][7] Market Data and Key Metrics Changes - LifeMD has over 322,000 active subscribers and receives more than 120,000 unique daily visitors to its websites, indicating strong brand strength and demand for services [3] - The company expects to cover over 220 million lives through expanded partnerships with third-party benefits partners by the end of Q2 2026 [15] Company Strategy and Development Direction - LifeMD is focused on leveraging artificial intelligence to enhance care delivery, diagnostics, and patient operations, with plans to launch an AI clinical decision support tool in the first half of 2026 [11][12] - The company aims to build a comprehensive technology platform that integrates emerging AI capabilities and insurance benefits to improve patient experience [15][16] - LifeMD is committed to expanding its pharmacy operations, which are now licensed in all 50 states, to support personalized compounded medications [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, citing record demand in weight management and a diversifying specialty care platform [17] - The company anticipates returning to adjusted EBITDA profitability in Q2 2026 after making significant investments in patient acquisition [23] - Management highlighted the importance of insurance enablement in driving customer acquisition and retention, with expectations of improved metrics in this area [15][64] Other Important Information - LifeMD's balance sheet is strong, with nearly $37 million in cash and no debt, providing financial flexibility for growth investments [3][22] - The company is seeing high demand for the oral Wegovy pill, which has significantly contributed to new patient acquisitions in the weight management segment [27][71] Q&A Session Summary Question: Demand for Wegovy pill and brand products - Management noted strong demand for the Wegovy pill since its launch in January, with nearly doubled new patient acquisition in the weight loss business [27] Question: Revenue model for Wegovy pill - The pricing for the Wegovy pill is typically around $249 per month, with healthy gross margins of approximately $100 per order [30] Question: Investments in Q1 2026 - The company plans to increase sales and marketing expenditures significantly, with a focus on driving patient acquisition while reducing customer acquisition costs [33] Question: Revenue ramp and drivers - Growth will primarily come from subscriber count increases in the GLP-1 weight management business, women's health, and the Rex MD brand [36] Question: Women's health performance compared to other markets - Initial performance in women's health shows high intent and promising retention rates, with significant investments made in marketing and advisor partnerships [43][45] Question: Stickiness of Wegovy pill versus injectable - Retention rates for the Wegovy pill are better than the injectable, but long-term retention is still to be determined [54] Question: Comparison with competitors - LifeMD differentiates itself through its own provider group and a comprehensive care platform, offering synchronous care and a range of specialty services [56][58] Question: Patient acquisition channels - The marketing strategy remains similar to past efforts, with new partnerships yielding strong performance in patient acquisition [62] Question: Lifetime value of covered patients versus cash pay patients - Management believes that patients using insurance will have better retention and lifetime value compared to cash pay patients, though this is still being validated [64][67] Question: In-house pharmacy fulfillment - Approximately 70% of fulfillment is handled in-house, leading to a margin improvement of 150-200 basis points [72]

Financial Data and Key Metrics Changes - LifeMD reported a revenue growth of 25% year-over-year for 2025, totaling $194.1 million, with a gross margin of 85.7%, a slight decrease of 50 basis points compared to the previous year [22][23] - The fourth quarter revenue grew 4% year-over-year to $46.9 million, with a gross margin of 87.1%, an expansion of 570 basis points from the prior year [20][21] - GAAP net income for the fourth quarter was $19 million or $0.41 per share, including a one-time benefit from the sale of WorkSimpli, while the adjusted EBITDA for the fourth quarter was $4.8 million, up from $1.1 million in the previous year [21][24] Business Line Data and Key Metrics Changes - The weight management business is experiencing record patient acquisition, with new signups approaching 700 per day, and customer acquisition costs have declined sequentially [4][19] - The men's health segment, represented by the Rex MD brand, has approximately 215,000 active patients and returned to growth in the second half of 2025 [8][19] - Women's health is a significant focus, with investments in launching this offering, including the acquisition of Optimal Human Health MD and partnerships with recognized experts in the field [5][6] Market Data and Key Metrics Changes - LifeMD has over 322,000 active subscribers and is onboarding approximately 1,200 new patients daily, reflecting strong brand demand [3][19] - The company expects to cover over 220 million lives through expanded partnerships with third-party benefits partners by the end of Q2 2026 [15][16] Company Strategy and Development Direction - LifeMD is focused on leveraging artificial intelligence to enhance care delivery, diagnostics, and patient operations, with plans to launch an AI clinical decision support tool in the first half of 2026 [11][12] - The company aims to build a comprehensive virtual healthcare platform that integrates emerging AI capabilities and insurance benefits, enhancing patient experience and operational efficiency [16][17] - LifeMD is committed to expanding its pharmacy operations, which are now licensed in all 50 states, to support personalized compounded medications and improve margins [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, citing record demand in weight management and a diversifying specialty care platform [18] - The company anticipates returning to adjusted EBITDA profitability in Q2 2026, with revenue guidance for 2026 projected between $220 million and $230 million [25] Other Important Information - LifeMD's balance sheet is strong, with nearly $37 million in cash and no debt, allowing for aggressive investment in growth initiatives [3][24] - The company is seeing significant pipeline opportunities with large pharmaceutical companies, enhancing its attractiveness as a partner in the healthcare space [5] Q&A Session Summary Question: Demand for Wegovy pill and brand products - Management noted strong demand for the Wegovy pill since its launch in January, with nearly doubled new patient acquisition in the weight loss business [29] Question: Revenue model for Wegovy pill - The Wegovy pill is typically priced at $249 per month, with healthy gross margins around $100 per order [31] Question: Investments in Q1 2026 - The company plans to increase sales and marketing expenditures significantly, expecting to drive patient acquisition and revenue growth [34] Question: Drivers of revenue increase in 2026 - Growth will primarily come from subscriber count increases in the GLP-1 weight management business, women's health, and the Rex MD brand [37] Question: Women's health performance compared to other markets - Early performance in women's health shows higher intent and promising retention rates, with significant investments made in marketing and brand development [44][46] Question: Stickiness of Wegovy pill versus injectable - Initial retention rates for the Wegovy pill are better than the injectable, but long-term retention remains to be seen [54] Question: Comparison with competitors like Amazon - LifeMD differentiates itself through its own provider group and a comprehensive care platform, offering synchronous care and a range of specialty services [56][58]

Financial Performance - Full year 2025 revenue grew 25% to $194.1 million, with adjusted EBITDA rising 309% to $15.3 million[6] - Fourth quarter revenue increased 4% to $46.9 million, while adjusted EBITDA rose 348% to $4.8 million[6] - Telehealth revenue for Q4 2025 reached $46.87 million, a 3.84% increase from $45.14 million in Q4 2024, and total revenue for the year was $194.06 million, up 25.19% from $154.82 million in 2024[21] - Gross profit for Q4 2025 was $40.84 million, representing a 11.43% increase from $36.75 million in Q4 2024, with total gross profit for the year at $166.34 million, up 24.73% from $133.38 million in 2024[21] - Net income attributable to LifeMD, Inc. for Q4 2025 was $19.96 million, a significant recovery from a net loss of $4.94 million in Q4 2024, with total net income for the year at $15.62 million compared to a loss of $20.86 million in 2024[21] - Basic earnings per share for Q4 2025 was $0.41, compared to a loss of $0.14 in Q4 2024, and for the year, it was $0.25 compared to a loss of $0.60 in 2024[21] Subscriber Growth - Active subscribers reached 322,872, marking a 16% year-over-year growth[9] Future Projections - For 2026, total revenue is expected to be in the range of $220 million to $230 million, representing 13% to 19% year-over-year growth[11] - Annualized run-rate revenue is projected to exceed $250 million by Q4 2026, driven by GLP-1 and women's health momentum[11] - Adjusted EBITDA is expected to be in the range of $12 million to $17 million for 2026, with a target of exceeding $25 million by Q4 2026[11] Cash and Debt Management - The company exited 2025 with $36.8 million in cash and no debt, positioning for accelerated growth investments[6] - Cash at the end of the year for continuing operations was $36,786,318, an increase from $32,651,801 at the end of 2024[25] - Cash used in financing activities for the year was $(788,562), down from $(934,903) in the previous year[25] Operating Expenses - Total expenses for Q4 2025 were $41.94 million, slightly up from $41.59 million in Q4 2024, with total expenses for the year at $174.01 million, an increase from $153.79 million in 2024[21] - The company reported a loss on debt extinguishment of $1,155,851 for the year ended December 31, 2025[29] - Stock compensation expense for the year was $10,496,321, compared to $12,234,797 in 2024[29] - The company incurred litigation costs of $2,273,355 for the year, up from $1,698,531 in 2024[29] - Financing transaction expenses for the year totaled $134,415, compared to $336,497 in 2024[29] Cash Flow Activities - Cash flows from operating activities of continuing operations showed a net cash used of $2.10 million in Q4 2025, compared to a cash provided of $0.26 million in Q4 2024, with total cash used for the year at $2.07 million compared to $14.36 million in 2024[24] - Cash paid for capitalized software costs in Q4 2025 was $1.76 million, compared to $1.60 million in Q4 2024, with total cash paid for the year at $7.65 million versus $6.74 million in 2024[24] - Net cash provided by investing activities of discontinued operations was $19.02 million in Q4 2025, compared to a cash used of $0.91 million in Q4 2024, with total cash provided for the year at $16.43 million compared to a cash used of $3.33 million in 2024[24] - The company reported a net cash used in financing activities of continuing operations of $0.78 million in Q4 2025, compared to $0.76 million in Q4 2024, with total cash used for the year at $12.63 million compared to $3.31 million in 2024[24] Product Launch and Market Position - The company successfully launched oral Wegovy, with over 80% of new weight management patients initiating branded therapy[6] - Medicare coverage for GLP-1 medications is anticipated to be a significant catalyst for growth[4] - LifeMD's benefits infrastructure is on track to cover approximately 220 million Americans by the end of Q2 2026[6]

Investor Presentation This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this presentation may be identified by the use of words such as: "believe," "expect," "anticipate," "project," "should," "plan," "will," "may," "intend," "estimate ...